FDA Sees Dramatic Rise in Monitoring Failures in Pharmaceutical Warning Letters
In a profound revelation for the pharmaceutical industry, new analysis indicates a shocking rise in monitoring-related failures noted by the FDA in their warning letters. A deep dive into 3,286 FDA warning letters, conducted by Eupry, showcases that nearly one-third of these communications cite issues concerning temperature control or environmental monitoring. The growth of these monitoring failures is staggering; between 2021 and 2025, they ballooned by nearly 200%, steadily rising every single year, signaling a persistent and troubling trend for pharmaceutical manufactures.
This detailed review, which includes letters related to finished pharmaceutical manufacturers, active pharmaceutical ingredient (API) producers, and compounding pharmacies, uncovers a systemic compliance gap that spans the entire supply chain. The analysis found that CGMP (Current Good Manufacturing Practice) violations, along with misbranding and the distribution of unapproved drug products, are among the leading themes in these FDA warnings. However, unlike the issues of misbranding, monitoring failures are characterized as preventable and, regrettably, recurring.
Christian Jacobsen, CEO and co-founder of Eupry, emphasizes that these alarming statistics reflect an underlying issue beyond isolated lapses in compliance: "Missing data points and disconnected calibration records create an illusion of control that outdated systems can’t sustain."
The stakes connected to receiving an FDA warning letter are incredibly high. When a letter cites monitoring shortcomings, any product associated with those systems is thrown into doubt, resulting in quarantine procedures, expensive third-party remediation efforts, and a severe decline in trust amongst partners and patients alike. Jacobsen elaborates on the ramifications, noting, "When an issue escalates to the point of receiving a public warning letter, it signifies a history of missed alarms and poor documentation practices. This indicates deeper flaws in an organization’s quality management infrastructure than just one isolated monitoring gap."
This problem of monitoring failures extends beyond budget constraints or insufficient technology. Jacobsen points to structural issues within organizations that often contribute to these lapses: "Centralized IT departments tend to acquire monitoring solutions, but the responsibility for equipment validation and continuous calibration is relegated to localized teams, creating a cumbersome manual burden. Companies have implemented digital solutions, but they often overlay new software atop outdated, fragmented processes."
To truly confront the challenges posed by monitoring failures, Jacobsen calls for a shift in perspective: validation, monitoring, and calibration should be managed collectively as one coherent system, rather than separate processes. Until such a unified approach is adopted, he warns, the concerning 30% failure rate in monitoring-related compliance is likely to persist.
In closing, the findings from Eupry underscore the significant implications of monitoring inadequacies within pharmaceutical manufacturing. With continuous monitoring being a core requirement under FDA CGMP guidelines, organizations are urged to reassess and improve their compliance infrastructures before facing detrimental consequences of failing to do so.
The Eupry analysis included all 3,286 FDA warning letters extracted from FDA.gov, filtering for 478 letters that fell under the pharmaceutical CGMP scope after removing irrelevant categories such as those related to food, veterinary applications, medical devices, and dietary supplements. Out of the identified letters, 145—or 30%—explicitly mentioned issues related to temperature and environmental monitoring, implying that the actual number of letters indicating any monitoring-related failures could be even higher. This data was compiled from the FDA Warning Letters portal as of early April 2026, which at that time included 3,286 entries. The portal is continuously updated, with the current count at 3,562 letters.
Eupry specializes in providing automated solutions for temperature and environmental monitoring tailored to the pharmaceutical and life sciences sectors, assisting organizations in transitioning from manual and disjointed compliance processes to a cohesive, ongoing monitoring ecosystem.
This detailed review, which includes letters related to finished pharmaceutical manufacturers, active pharmaceutical ingredient (API) producers, and compounding pharmacies, uncovers a systemic compliance gap that spans the entire supply chain. The analysis found that CGMP (Current Good Manufacturing Practice) violations, along with misbranding and the distribution of unapproved drug products, are among the leading themes in these FDA warnings. However, unlike the issues of misbranding, monitoring failures are characterized as preventable and, regrettably, recurring.
Christian Jacobsen, CEO and co-founder of Eupry, emphasizes that these alarming statistics reflect an underlying issue beyond isolated lapses in compliance: "Missing data points and disconnected calibration records create an illusion of control that outdated systems can’t sustain."
The stakes connected to receiving an FDA warning letter are incredibly high. When a letter cites monitoring shortcomings, any product associated with those systems is thrown into doubt, resulting in quarantine procedures, expensive third-party remediation efforts, and a severe decline in trust amongst partners and patients alike. Jacobsen elaborates on the ramifications, noting, "When an issue escalates to the point of receiving a public warning letter, it signifies a history of missed alarms and poor documentation practices. This indicates deeper flaws in an organization’s quality management infrastructure than just one isolated monitoring gap."
This problem of monitoring failures extends beyond budget constraints or insufficient technology. Jacobsen points to structural issues within organizations that often contribute to these lapses: "Centralized IT departments tend to acquire monitoring solutions, but the responsibility for equipment validation and continuous calibration is relegated to localized teams, creating a cumbersome manual burden. Companies have implemented digital solutions, but they often overlay new software atop outdated, fragmented processes."
To truly confront the challenges posed by monitoring failures, Jacobsen calls for a shift in perspective: validation, monitoring, and calibration should be managed collectively as one coherent system, rather than separate processes. Until such a unified approach is adopted, he warns, the concerning 30% failure rate in monitoring-related compliance is likely to persist.
In closing, the findings from Eupry underscore the significant implications of monitoring inadequacies within pharmaceutical manufacturing. With continuous monitoring being a core requirement under FDA CGMP guidelines, organizations are urged to reassess and improve their compliance infrastructures before facing detrimental consequences of failing to do so.
Notes to editors
Methodology
The Eupry analysis included all 3,286 FDA warning letters extracted from FDA.gov, filtering for 478 letters that fell under the pharmaceutical CGMP scope after removing irrelevant categories such as those related to food, veterinary applications, medical devices, and dietary supplements. Out of the identified letters, 145—or 30%—explicitly mentioned issues related to temperature and environmental monitoring, implying that the actual number of letters indicating any monitoring-related failures could be even higher. This data was compiled from the FDA Warning Letters portal as of early April 2026, which at that time included 3,286 entries. The portal is continuously updated, with the current count at 3,562 letters.
About Eupry
Eupry specializes in providing automated solutions for temperature and environmental monitoring tailored to the pharmaceutical and life sciences sectors, assisting organizations in transitioning from manual and disjointed compliance processes to a cohesive, ongoing monitoring ecosystem.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.